Trial Profile
A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Linezolid (Primary) ; Pretomanid (Primary) ; Clofazimine; Moxifloxacin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TB-PRACTECAL
- 22 Dec 2022 Primary endpoint has been met. (Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up), as per Results published in the New England Journal of Medicine
- 22 Dec 2022 Results published in the New England Journal of Medicine
- 02 Aug 2022 Results assessing efficacy and safety of regimens in the HIV coinfected patients, presented at the 24th International AIDS Conference.